Back to Index

Kadmon Corporation Presents Data Demonstrating Potential of ROCK2 Inhibition to Treat Lupus

— Data Presented at Federation of Clinical Immunology Societies (FOCIS) Annual Meeting —

NEW YORK, June 22, 2015 – Kadmon Corporation, LLC, today announced preclinical data demonstrating the therapeutic potential of inhibiting ROCK2 (Rho-associated coiled-coil kinase 2) to treat systemic lupus erythematosus (SLE). The data will be described in an oral presentation at the Federation of Clinical Immunology Societies (FOCIS) 2015 meeting, taking place June 24-27 in San Diego. The data were previously presented at the American Association of Immunologists (AAI) Annual Meeting in May 2015.

Kadmon has demonstrated in a variety of preclinical models that ROCK2 inhibition with KD025, the Company’s potent and highly selective inhibitor of ROCK2 currently in Phase 2 clinical development, has potential to treat SLE and other autoimmune and fibrotic diseases. The data presented show that oral administration of KD025 blocked progression of SLE in an Mrl/lpr murine model, as documented by a substantial improvement in both histological and clinical scores of KD025-treated animals. Importantly, the data demonstrate the cellular mechanism by which ROCK2 inhibition regulates immune cell responses: ROCK2 controls the development and function of T follicular helper (Tfh) cells that are essential to generate high-affinity antibodies and B cell memory, but are aberrantly activated in SLE patients. The data support the mechanism of targeted ROCK2 inhibition to rebalance the immune response in SLE and other autoimmune conditions.

“ROCK2 inhibition represents an important approach to treat lupus, a painful, debilitating autoimmune disease with limited therapeutic options,” said Peter Lipsky, M.D., Scientific Advisor, Alliance for Lupus Research and the Lupus Research Institute. “These data provide encouraging results that KD025 will be effective in treating lupus in the clinical setting.”

“Kadmon has demonstrated the importance of ROCK2 signaling across a variety of disease settings, including in lupus,” said John L. Ryan, Ph.D., M.D., Executive Vice President and Chief Medical Officer at Kadmon. “These data support our continued clinical development of KD025 for the treatment of autoimmune and fibrotic diseases.”

The abstract titled, “ROCK2 signaling is required for development and function of T follicular helper cells in SLE,” (Abstract #3586) will be presented on Thursday, June 25 at 3:30 p.m. PT by Jonathan Weiss, Ph.D., Senior Scientist, Immunology at Kadmon.

About Kadmon Corporation
Kadmon Corporation, LLC, is a vertically integrated biopharmaceutical company focused on developing innovative products for significant unmet medical needs. We have a diversified product pipeline in autoimmune and fibrotic diseases, oncology, monogenic diseases and metabolic disease. For more information, visit

This press release contains forward-looking statements. These forward-looking statements are based on management’s expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. The information contained in this press release is believed to be current as of the date of original issue. Kadmon expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Contact Information
Ellen Tremaine, Investor Relations